Prevention by somatostatine and N-acetylcisteine of multiorgan failure mediated by oxidative stress after intestinal ischemia.
Ferrer
J V
JV
Department of Surgery, Hospital de Navarra, Pamplona, Spain.
Ariceta
J
J
Guerrero
D
D
Balén
E
E
Herrera
J
J
Lera
J M
JM
D000111:Acetylcysteine / Q000627:therapeutic use*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D005978:Glutathione / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D007421:Intestine, Small / Q000098:blood supply*; D007511:Ischemia / Q000150:complications* / Q000503:physiopathology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008315:Malondialdehyde / Q000378:metabolism; D008638:Mesenteric Arteries; D009102:Multiple Organ Failure / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D018384:Oxidative Stress; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D013004:Somatostatin / Q000627:therapeutic use*
D008315:Malondialdehyde; D013004:Somatostatin; D000493:Allopurinol; D000255:Adenosine Triphosphate; D009195:Peroxidase; D005978:Glutathione; D000111:Acetylcysteine